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Summary
The concept of using total lymphoid irradiation (TU)
for immunosuppression is based on the prolonged
and profound immunosuppressive effects observed
a~er TU in the treatment of patients with Hodgkin's
disease. Pre-operative TU of allograft recipients has
been shown to be immunosuppressive when used
alone or together with chemical immunosuppression.
Fractionated TU and allogeneic bone marrow injec-
tIOns produce stable chimaerism wilhout graft-
versus-host disease in inbred mice, rats and mongrel
dogs and transplantation tolerance of skin and
cardiac grafts in rats. In the primate, TU and bone
marrow injection result in siQnificant tolerance of
liver and Kidney allogmfts. In 1959 subletl'ial whole-
body irradiation was used as an immunosuppressive
agent for the first successful related-human renal
allografts between non-identical twins. Despite the
dangers of myelosuppression, recent clinical experi-
ence has shown TU to be a useful immunosuppres-
sant fOr organ transplantation, allowing decreased
dosage of concomitant immunosuppressive drugs.
S Atr Med J 1987; 71.: 445-447.
In the past 10 years total lymphoid irradiation (TU) has been
show~ ~o bea potent immunosuppressive ar-ent with potential
for clImcal use ID organ allotransplantation. -3 While indefinite
allograft survival with induction of donor-specific tolerance is
the desired goal in organ transplantation research, the role of
TLI in achieving this end remains controversial. The ability of
TLI to ensure prolonged organ allograft survival across minor
and major histocompatibility barriers is well established, but
st~dies in experimental models have yielded conflicting results
WIth respect to induction of tolerance.
. In this review, the experimental studies and clinical applica-
tion of TU will be discussed.
Biological effects of TU
Most research workers using TLI for immunosuppression
have administered electromagnetic photons either as X- or 1'-
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rays. Modern megavoltage radiotherapy is administered either
as beams of X-rays produced by linear electron accelerators or
as 1'-rays produced by cobalt-60 teletherapy units.4
The radiations interact with "matter to ionise atoms and
initiate a cascade of physiochemical reactions during which
abnormal chemical bonds may be formed or broken. Cells
k.illed by irradiatio~die as a result of changes in the configura-
tI?~ .of I?~A. whIch c.ause death during attempted mitotic
d~v1Sl0n~.' HIghly radIosensitive, small, resting lymphocytes
dIe durmg the interphase before mitosis. Radiation injures
small and large molecules indiscriminately and has no selective
effect on DNA.4 The mitotic death is accompanied by chromo-
somal breaks, translocations, bridges and other structural
abnormalities which reflect the production of lesions in chro-
mosomal DNA and which may be single- or double-strand
breaks or damage to pyrimidine and purine basesY It has
been reported that base damage and single-strand breaks are
readily repaired enzymatically, whereas double-strand breaks,
though less numerous, are much less susceptible to repair and
are therefore usually lethal for the cell.
Earli~r research workers6 showed that whole-body irradiation
results m lymphocytopenia and suppresses antibody production.
About 80% of lymphocytes die a prompt intermitotic death
afte.r ionisi~g irradiation, while 20% survive. B cells are quite
radlosenslt1ve and undergo both interphase and mitotic death
following irradiation, and like them, the sensitive suppressor
T-cell precursors. may undergo interphase death. The homing
potentIal of cells IS also affected by radiation.6
It is of interest that the effects of whole-body irradiation are
qualitatively and quantitatively different from those of localised
or regional radiation.6
Immunosuppressive properties of TU
The ra~ionale for the application of TLI as immunosuppressive
agent IS based on the findings of suppression of T -cell and
preservation of B-cell function without apparent increased
susceptibility to infection in irradiated patients with Hodgkin's
dis~ase.,,7,8 T~e findings of T-lymphocytopenia, B-lymphocy-
t?SIS, depreSSIOn of responsiveness in mixed lymphocyte reac-
tI~n and to phytohaemagglutinin (PHA) mitogenesis, together
WIth a loss of delayed-type hypersensitivity response to rechal-
lenge with skin sensitivity agents has stimulated other workers
to consider TLI as a potential immunosuppressive agent in
organ allotransplantation. 5 Immunological monitoring after TLI
and transplantation have confirmed a sustained and uniform
reduction in helper-inducer T cells and in the proliferative
responses. to PHA, pokeweed mitogen and allogeneic lympho-
cytes dunng the first year after grafting. A variable recovery in
the absolute number of suppressor-cytotoxic cells and the
proli~erative response to concanavalin A has been reported.
StudIes of T -cell recovery in Hodgkin's disease treated with
TL.I have consistently shown a more rapid recovery of cyto-
toxIc-suppressor cells and a slower recovery of helper-inducer
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cells. T -cell maturation or recovery after completion of TLI
may reduce its potency as an immunosuppressive agent, hence
the imponance of early allografting after completion of TLP
In experimental models the administration of cyclophospha-
mide between the completion of TLI and allografting prevents
the recovery of peripheral blood OKT4- and OKT8-reactive
lymphocytes. lo In these studies T -cell subsets were identified
by indirect immunofluorescent antibody techniques using
monoclonal antibodies OKT4 and OKT8 as the primary anti-
bodies. 10
Experimental studies
Slavin el al. I were the first to show significant skin-graft
survival after TLI in H2-incompatible strains of mice. They
showed considerable skin-graft survival in Balb-C mice con-
ditioned with 200 rad!d 5 times per week to a total of 3400
rad. In addition, these authors showed that a single injection
of bone marrow produced stable chimaeras in similarly TLI-
treated recipients. I Of imponance in these early experiments
was that chimaeras could be established by transfer of fully
allogeneic bone marrow cells without induction of graft-versus-
host disease.
Subsequent studies have shown impressive long-term cardiac
allograft survival in mongrel dogs and rhesus and cynomolgus
monkeys. I H 3 Concomitant administration of azathioprine
(AZA), anti-human thymocyte globulin (ATG) and cyclosporin
A (CSA~ _was needed to ,;n~~re consistent and p~olonged
survival. I II Myburgh er al. _,I 16 and Smn el al., 17 usmg TLI
in a major study in primates, showed long-term kidney allograft
survival either with or without concurrent bone marrow trans-
plantation. Full tolerance for kidney and liver allografts was
obtained with cumulative doses ranging from 600 to 2800
rad. 2 However, radiation-related deaths occurred with
increasing frequency with cumulative doses of 2000 rad and
more. The administration of CSA in combination with sub-
optimal TLI in the same baboon kidney transplantation model
resulted in inferior graft survival rates compared with TLI
alone. A synergistic or additive effect could not be
demonstrated.2
Du Toit el al. 18-20 showed poor pancreatic allograft survival
after TLI in a baboon allograft model. However, the admini-
stration of 800 rad subtotal marrow irradiation together with
CSA resulted in considerable and consistent pancreatic allograft
survival, results previously not achieved with TLI alone.21 In
contrast, other workers22,23 showed minimal pancreatic allograft
survival after TLI in mongrel dogs and primates.
Fields of irradiation
Significant prolongation of organ allograft survival in experi-
mental models has been achieved with whole-body and subtotal
marrow irradiation. 24-29 In all the experimental models the
fields irradiated have been much more extensive than the
mantle and invened-Y fields used in patients with Hodgkin's
disease. In the baboon, extensive fields are needed if prolonged
engraftment of pancreas, kidneys and liver are to be achieved.2
This has necessitated irradiation of the entire trunk below the
base of the skull and includes thorax, abdomen, pelvis, proximal
femurs and humeri, and tail. 2.21 In rats, dogs and monkeys,
similar extensive fields are needed. 13,24.27 Current studies in
man have indicated, however, that the conventional fields used
in the treatment of Hodgkin's disease are adequate.3,30,31
Need for concomitant immunosuppression
Although TLI alone is adequate for the establishment of
marrow graft acceptance in outbred mongrel dogs, further
immunosuppression is needed to obtain consistent engraftment
of the heart, pancreas and kidney in cynomolgus monkeys,
baboons and man.3,11,13,21,32 In extensive studies over IS years,
Myburgh er al. 2,15,16 showed extended renal and liver allograft
survival in baboons treated with fractionated TLI only. Many
animals in that series have survived for more than 5 years with
no need for concomitant immunosuppression.2
NeverTheless, the current consensus is that maintenance
immunosuppressive therapy is indic~ted after TLI and engraft-
ment in human allograft recipients. ,., Rejection has frequently
been reported after cessation of maintenance chemical immu-
nosuppression in TLI allograft recipients.9
In most studies ATG, steroids and AZA have been used as
adjunctive drugs,3,24 but in some patients severe myelosup-
pression has followed the use of AZA and TLP The efficacy
of TLI together with CSA remains to be shown in man
although results in a baboon pancreatic transplantation model
have been encouraging.21
Human experience
To date approximately 50 patients have been 'treated with
fractionated TLI before renal transplantation.3,10 In most
studies TLI has resulted in effective immunosuppression for
organ transplantation. The majority of patients have been
renal allograft recipients and have needed concomitant
immunosuppressive treatment to prevent rejection.3,1O In one
study, cessation of adjunctive treatment resulted in rejection of
the kidney.9 The observation underlines the importance of
maintenance immunosuppression after TLI or the need for
'topping-up' irradiation either pre- or postoperatively.5 In
most studies modest complications were observed during and
after TLI, sometimes necessitating interruption of the radiation
therapy.3 Nearly all patients suffered from nausea, vo~iting,
increased fatigue, leucopenia and thrombocytopenia."1O An
increased susceptibility to infection, particularly herpes simplex
and cytomegalovirus infections, was observed in some
. patients.3,1O The majority of Eatients received irradiation to
mantle and inverted-Y fields. ,10,30 In Najarian el al.'s3 study,
optimal results were achieved with 2500 rad delivered in 100-
rad fractions followed by transplantation within 2 weeks,
followed by a tapering prednisone schedule and maintenance
AZA. In addition the administration of donor bone marrow at
the time of transplantation did not produce chimaerism.
Disadvantages of TU include the need for additional pharma-
cological immunosuppression and the problem of maintenance
of patients in a state of readiness over the period between the
end of TLI conditioning and organ transplantation.
In view of the recent advances in pharmacological immuno-
suppressive therapy, particularly with CSA, TLI seems unsuit-
able for use solely as a means of routine nonspecific immuno-
suppression.
Radiation-related complications
Apart from the interference with host defence mechanisms,
TLI has a profound effect on the bone marrow. Common
complications include leukopenia and thrombocytopenia,
resulting in an increased susceptibility to infection and a
bleeding diathesis. 3,1O An increase in complications can be
expected with the addition of concomitant chemical immuno-
suppression.
Gastro-intestirial complications of TLI include anorexia,
nausea and vomiting, and may necessitate interruption of the
preparative radiation therapy, hospitalisation and nutritional
support with intravenous hyperalimentation.3Degrees of weight
loss and anaemia have been reported in experimental models
and in man.3,21 Diabetic patients tolerate radiation less well
and seem to experience more severe weight loss and gastro-
intestinal symptoms than their non-diabetic counterparts.3
Infections frequently reported after TLI include her~es
simplex, herpes zoster and cytomegalovirus infections. ,10
Improvement has been reported after treatment in selected
cases with the antiviral drug acyclovir. In many patients,
cultures for Epstein-Barr virus are positive.3,10
Radiation-induced mutagenesis is of concern in all patients
receiving TLI.6 However, the risk of leukaemia or lymphoma
is not increased in patients with Hodgkin's disease treated
with 4400 rad TLI alone.9 Unfortunately, the effects of
uraemia and the addition of ATG or CSA to TLI are not
known. 9 Nevertheless, the development of lymphoma in a
small number of renal allograft recipients has recently been
reported by Najarian er al. 3 Pennock er al. 13 have also reported
the occurrence of metastatic lymphoma after TLI and CSA
immunosuppression in cynomolgus monkeys which received
cardiac allografts. The development of lymphoma after TLI in
baboons has never been reported.2,21 .
On balance, the side-effects of TLI seem to compare favour-
ably with those of other immunosuppressive regimens.
Conclusion
TLI has been shown to be a potent immunosuppressive agent
in experimental models and in man. The need for administra-
tion of donor bone marrow remains to be demonstrated. In
man, the addition of concomitant pharmacological immunosup-
pression is a prerequisite if prolonged survival of allografts is
to be ensured. TLI produces stable chimaeras in rodents and
full tolerance for kidney and liver allografts in primates.
Laboratory and clinical experience suggest that optimal results
are achieved by immediate organ engraftment after completion
of TLI. Frequently, the clinical use of TLI is compromised
because a suitable allograft is not available at the time a
potential recipient completes a course of TLI.
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